Mucocutaneous leishmaniasis and HIV.
Mucocutaneous leishmaniasis is a rare disease in Europe. Relapses after treatment are more frequent than in visceral leishmaniasis. HIV patients infected by Leishmania have frequently visceral involvement, and responses to treatment are poor. Mucocutaneous leishmaniasis in HIV-infected patients has rarely been reported. A patient with centrofacial granuloma was diagnosed as having mucocutaneous leishmaniasis; simultaneously HIV infection was detected. To our knowledge this is the first case acquired in Europe. Intravenous meglumine antimonate 20 mg/kg/day for 28 days was proven to be useful.
Miralles
E S
ES
Servicio de Dermatología, Universidad de Alcalá de Henares, Hospital Ramón y Cajal, Madrid, Spain.
Núñez
M
M
Hilara
Y
Y
Harto
A
A
Moreno
R
R
Ledo
A
A
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D006801:Humans; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate